Company Overview and News

 
Champion Iron Limited Announces Annual General Meeting Voting Results

2018-08-20 globenewswire
MONTREAL, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (ASX: CIA, TSX: CIA)(“Champion” or the “Company”) advises that at an Annual General Meeting of the Company’s shareholders (the “Meeting”) which was held in Montreal, Quebec on August 17, 2018, the following resolutions were passed by the requisite majorities by a vote by way of show of hands and by ballot as follows:
CHPRF CIA CIA

 
Champion Iron Intersects Several Zinc-rich Intervals at Its Powderhorn Project, Newfoundland

2018-08-15 globenewswire
MONTREAL, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (TSX: CIA, ASX:CIA) reports that its wholly-owned subsidiary Champion Iron Mines Limited (the “Company” or “Champion”) is pleased to disclose results of recent exploration drilling at its Powderhorn property, located in North Central Newfoundland, 40 km southwest of the town of Springdale. This program intersected several zinc (“Zn”) rich intervals, including drill hole PH18-01 which intersected 3.
CHPRF CIA CIA

 
Champion Iron Appoints New Chief Financial Officer

2018-08-14 globenewswire
MONTRÉAL, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (TSX: CIA) (ASX: CIA) (“Champion” or the “Company”) is pleased to announce the appointment of Ms. Natacha Garoute, LLB, CPA, CA, as the Company’s Chief Financial Officer.
CHPRF CIA CIA SEMFF

 
Champion Iron Corporate Update: Strong FY2019 First Quarter Results as Bloom Lake Iron Ore Mine Produces 2,166,000 Tonnes During Ramp-Up

2018-08-13 globenewswire
MONTRÉAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (TSX:CIA) (ASX:CIA) (“Champion Iron” or “The Company”) is pleased to announce that, with the successful production ramp-up of its Bloom Lake Iron Ore Mine (“Bloom Lake”), it reported strong operational and financial results for the 2019 financial year first quarter ended June 30, 2018 (see Champion Iron’s filings on SEDAR dated August 7, 2018).
CHPRF CIA CIA

 
Quebec Iron Ore to Ship First Vessel of High Quality Canadian Iron Ore From Sept-Îles to Asia

2018-03-27 globenewswire
MONTRÉAL, March 27, 2018 (GLOBE NEWSWIRE) -- Quebec Iron Ore Inc. (“QIO”), a Champion Iron Limited (ASX:CIA) (TSX:CIA) (“Champion” or the “Company”) subsidiary, is pleased to announce that preparation for the first shipment of Bloom Lake Iron Ore Mine (“Bloom Lake”) high quality iron ore is underway following the arrival of the MV Magnus Oldendorff at the Port of Sept-Îles on March 25, 2018.
CHPRF CIA CIA

 
Minerai de fer Québec annonce le chargement de son premier vaisseau de concentré de fer canadien de haute qualité vers l’Asie

2018-03-27 globenewswire
MONTRÉAL, 27 mars 2018 (GLOBE NEWSWIRE) -- Minerai de fer Québec Inc. (« MFQ »), une filiale de Champion Iron Limited (ASX: CIA)(TSX: CIA) (la «société» ou «Champion»), a confirmé aujourd’hui que le premier chargement de concentré de fer de haute qualité, en provenance de la mine de fer du Lac Bloom, a débuté le 25 mars 2018 à la suite de l’arrivée du MV Magnus Oldendorff au Port de Sept-Îles.
CHPRF CIA CIA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:CIA / CHAMPION IRON LIMITED on message board site Silicon Investor.

Robotics and Artificial Intelligence Robotics and Artificial Intelligence Robotics and Artificial Intelligence The Financial Collapse of 2001 Unwinding The Financial Collapse of 2001 Unwinding The Financial Collapse of 2001 Unwinding
Specially made small condoms for Soy Boy Libtards Specially made small condoms for Soy Boy Libtards Specially made small condoms for Soy Boy Libtards Socialized Education - Is there abetter way? Socialized Education - Is there abetter way? Socialized Education - Is there abetter way?
The Judiciary The Judiciary The Judiciary Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing
Acacia Communications Acacia Communications Acacia Communications A Review of TV Commercials: The Good, The Bad, u0026 The Ugly A Review of TV Commercials: The Good, The Bad, u0026 The Ugly A Review of TV Commercials: The Good, The Bad, u0026 The Ugly
Commercial Real Estate tic.............tic,,, Commercial Real Estate tic.............tic,,, Commercial Real Estate tic.............tic,,, FBN Associates - Year 2000/Y2K IPO!!! FBN Associates - Year 2000/Y2K IPO!!! FBN Associates - Year 2000/Y2K IPO!!!